Diagnostic test accuracy of 18F-FDG PET/CT for prediction of programmed death ligand 1 (PD-L1) expression in solid tumours: a meta-analysis

Glucose metabolism involved in PD-L1-mediated immune escape in the malignant kidney tumour microenvironment

(2021) Yongbo Yu et al.   Cell Death Discovery

18F-FDG maximum standard uptake value predicts PD-L1 expression on tumor cells or tumor-infiltrating immune cells in non-small cell lung cancer

(2020) Bingxin Hu et al.   ANNALS OF NUCLEAR MEDICINE

Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma

(2020) Bingxin Hu et al.   NUCLEAR MEDICINE COMMUNICATIONS

FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer

(2020) Tomoko Hirakata et al.   BREAST CANCER RESEARCH AND TREATMENT

Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma

(2020) Maria Togo et al.   BRITISH JOURNAL OF CANCER

Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma

(2020) Kengo Kuriyama et al.   CANCER SCIENCE

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

(2020) Raju K. Vaddepally et al.   Cancers

Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer

(2019) Ruohua Chen et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

18F-FDG PET/CT imaging in pulmonary sarcomatoid carcinoma and correlation with clinical and genetic findings

(2019) Xiaodong Wu et al.   ANNALS OF NUCLEAR MEDICINE

Immuno-oncology drug development goes global

(2019) Jia Xin Yu et al.   NATURE REVIEWS DRUG DISCOVERY

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

(2019) Andrew A. Davis et al.   Journal for ImmunoTherapy of Cancer

Relationship between PD-L1 expression and 18F-FDG uptake in gastric cancer

(2019) Ruohua Chen et al.   Aging-US

Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma

(2017) Minghui Zhang et al.   Oncotarget

Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography

(2017) Kazuki Takada et al.   Cancer Medicine

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

(2015) Kristin J. Lastwika et al.   CANCER RESEARCH

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies

(2013) Penny F. Whiting   ANNALS OF INTERNAL MEDICINE

Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer

(2013) Kyoichi Kaira et al.   LUNG CANCER

The binomial distribution of meta-analysis was preferred to model within-study variability

(2007) Taye H. Hamza et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY